Morgan Stanley Bullish on Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290.

In a different corporate update, dated November 24, Eli Lilly reported that it will present the latest data from its breast cancer pipeline at the San Antonio Breast Cancer Symposium (SABCS). This symposium will take place from December 9 to 12. These findings reflect Lilly’s ongoing progress across core mechanisms in HR+, HER2– breast cancer, which is the most prevalent breast cancer subtype.

Morgan Stanley Bullish on Eli Lilly and Company (LLY)

Photo by Myriam Zilles on Unsplash

Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, commented:

“At SABCS 2025, we’re proud to showcase new data across our portfolio of investigational and approved breast cancer medicines, addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K. Together, these presentations reflect the continued momentum of Lilly’s breast oncology portfolio and our commitment to translating biologic conviction into meaningful progress for people living with breast cancer.”

Eli Lilly and Company (NYSE:LLY) is an Indianapolis-based company that develops, manufactures, and markets pharmaceuticals for diabetes, oncology, autoimmune and inflammatory diseases, mental health, and pain management globally.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Dow 20 Stocks List: Ranked By Hedge Fund Bullishness Index and 10 Unstoppable Dividend Stocks to Buy Now.

Disclosure. None.